1-5 of 5
Daniel H. Ryan, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission

Tara L. Lin, MD, Daniel H. Ryan, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1316.
https://doi.org/10.1182/blood-2019-124552
Published: 2019
Journal Articles

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy

Jonathan E. Kolitz, MD, Daniel H. Ryan, MD, Laura F. Newell, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Gary J. Schiller, MD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3856.
https://doi.org/10.1182/blood-2019-124553
Published: 2019
Journal Articles

Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Daniel H. Ryan, MD, Laura F. Newell, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Richard M. Stone, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3842.
https://doi.org/10.1182/blood-2019-124516
Published: 2019
Journal Articles

Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial

Jeffrey E. Lancet, MD, Antje Hoering, PhD, Geoffrey L. Uy, MD, Jorge E. Cortes, MD, Laura F Newell, MD, Tara L. Lin, Ellen K. Ritchie, MD, Robert K. Stuart, MD, Stephen A. Strickland, Donna Hogge, MD PhD FRCPC, Scott R. Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, MD PhD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Daniel H. Ryan, MD, Michael T. Chiarella, Arthur C. Louie, MD, Bruno C. Medeiros, MD
Journal: Blood
Blood (2016) 128 (22): 906.
https://doi.org/10.1182/blood.V128.22.906.906
Published: 2016
Journal Articles

Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

Bruno C. Medeiros, MD, Jeffrey E. Lancet, MD, Jorge E. Cortes, MD, Laura F Newell, MD, Tara L. Lin, Ellen K. Ritchie, MD, Robert K. Stuart, MD, Stephen A. Strickland, Donna Hogge, MD PhD FRCPC, Scott R. Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, MD PhD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Daniel H. Ryan, MD, Antje Hoering, PhD, Michael T. Chiarella, Arthur C. Louie, MD, Geoffrey L. Uy, MD
Journal: Blood
Blood (2016) 128 (22): 902.
https://doi.org/10.1182/blood.V128.22.902.902
Published: 2016